Macrophage EP4 Deficiency Drives Atherosclerosis Progression via CD36-Mediated Lipid Uptake: A Technical Review

Study Background and Research Question

Atherosclerosis remains the leading cause of cardiovascular mortality worldwide, primarily due to the development of lipid-rich plaques within arterial walls (Tang et al., 2025). Macrophages are central to plaque initiation and progression, orchestrating lipid uptake, foam cell formation, and inflammatory signaling. Despite the recognized role of prostaglandin E2 (PGE2) signaling in cardiovascular homeostasis, the specific contribution of its EP4 receptor on macrophage function during atherosclerosis has been unclear. This study addresses whether macrophage EP4 expression modulates atherogenesis through effects on lipid metabolism and immune polarization.

Key Innovation from the Reference Study

The principal innovation of Tang et al. (2025) lies in directly linking myeloid-specific EP4 deficiency to accelerated atherosclerosis via upregulation of CD36 and enhanced M1 macrophage polarization (Tang et al., 2025). By integrating genetic mouse models and multi-omics profiling, the study clarifies a mechanistic axis—EP4/CD36—that bridges prostaglandin signaling, lipid uptake, and immune activation within the plaque microenvironment. This mechanistic clarity advances the field beyond descriptive findings, identifying EP4 as a critical modulator of plaque stability and composition.

Methods and Experimental Design Insights

The research employed a robust combination of in vivo and in vitro techniques:

• Generation of myeloid-specific EP4 knockout mice on an ApoE-deficient background, a model highly susceptible to atherosclerosis when fed a Western diet.
• 16-week Western diet feeding to induce advanced atherogenesis.
• Histological analysis of aortic root sections to quantify plaque size and composition.
• Immunohistochemistry and lipid staining to assess foam cell formation and macrophage infiltration.
• In vitro stimulation of bone marrow–derived macrophages with oxidized LDL to study lipid uptake and polarization states.
• Transcriptomic (RNA-seq) and proteomic analyses to map downstream mediators and pathway alterations.
• qPCR and Western blotting to validate CD36 upregulation and polarization markers at the molecular level.

This integrative approach enables both phenotypic and mechanistic dissection of macrophage-specific EP4 loss in atherosclerosis.

Protocol Parameters

• mouse genotyping assay | PCR-based, ~1–2 hours per run | supports transgene detection and gene knockout validation in murine models | rapid and accurate identification of genetic modifications essential for colony management | workflow_recommendation
• Western diet feeding | 16 weeks | induces advanced atherosclerosis in ApoE-deficient mice | aligns with established models for studying late-stage plaque development | paper
• oxLDL stimulation of macrophages | 50 μg/mL, 24 hours | in vitro modeling of foam cell formation and polarization | permits controlled assessment of lipid uptake and gene expression | paper
• qPCR for gene expression | 10–50 ng cDNA/reaction | quantifies transcriptional changes in CD36, M1/M2 markers | provides molecular readout of polarization and lipid uptake pathways | paper
• PCR master mix with dye reagents | 2X premix, direct use from lysate | streamlines mouse genotyping and downstream validation | reduces hands-on time and error rates in routine assays | product_spec

Core Findings and Why They Matter

Key observations from Tang et al. (2025):

• EP4 expression is downregulated in atherosclerotic plaques and oxLDL-stimulated macrophages, implicating a role in disease progression.
• Myeloid-specific EP4 knockout mice develop significantly larger and more unstable plaques compared to controls, as demonstrated by histological assessment (Tang et al., 2025).
• Loss of EP4 promotes foam cell formation and shifts macrophages toward the pro-inflammatory M1 phenotype, as evidenced by increased expression of CD36, iNOS, and TNF-α, and decreased Arg1 and CD206.
• Transcriptomic and proteomic analyses reveal that CD36 is a critical effector downstream of EP4, mediating increased lipid uptake and inflammatory polarization.
• Validation via qPCR and immunoblotting confirms upregulation of CD36 and M1 markers in EP4-deficient macrophages.

These findings establish the EP4–CD36 axis as a regulator of lipid accumulation and inflammatory tone within the atherosclerotic plaque, highlighting a potential therapeutic target for stabilizing plaques and reducing cardiovascular risk.

Comparison with Existing Internal Articles

Recent internal reviews have emphasized the operational and mechanistic demands of mouse genotyping and immune cell lineage tracing in cardiovascular models. For example, the article Redefining Mouse Genotyping: Mechanistic Precision and Streamlined Workflows contextualizes how high-fidelity DNA extraction and PCR amplification technologies, such as the Direct Mouse Genotyping Kit Plus, are essential for validating complex genetic knockouts and transgene insertions in studies like Tang et al. (2025). Similarly, Empowering Translational Mouse Genetics discusses the convergence of rapid genotyping solutions with the growing sophistication of immune phenotyping and mechanistic cardiovascular research. Compared to these reviews, the reference paper stands out by providing direct evidence for a functional link between a genetic receptor pathway (EP4) and atherosclerosis progression, validated through both genetic and molecular assays. The need for rapid, accurate genotyping—highlighted in these internal articles—is clearly supported by the multi-layered experimental design of Tang et al., which relies on precise animal model construction and downstream molecular validation.

Limitations and Transferability

While the study robustly maps the EP4–CD36 axis in murine macrophages, several limitations warrant attention:

• The findings are limited to ApoE-deficient mouse models and may not fully extrapolate to human atherogenesis without further validation.
• Although multi-omics approaches strengthen mechanistic claims, the precise upstream signals regulating EP4 downregulation in vivo remain to be elucidated.
• Potential compensatory effects from other PGE2 receptors or lipid uptake pathways were not comprehensively assessed.
• Longitudinal or interventional studies with EP4 agonists are needed to confirm therapeutic potential.

Nonetheless, the study's integrative framework and use of advanced genotyping and molecular validation protocols enhance its transferability to other models of chronic inflammation and lipid metabolism.

Research Support Resources

For researchers aiming to replicate or extend these findings, reliable mouse genotyping and colony management are critical. The Direct Mouse Genotyping Kit Plus (SKU K1027) enables rapid extraction and direct PCR amplification of genomic DNA from mouse tissues, supporting streamlined workflows for gene knockout validation, transgene detection, and animal colony genetic screening (source: product_spec). Its pre-mixed PCR master mix with dye reagents reduces hands-on time and enhances reproducibility in mouse genotyping assays. For more insights on integrating this technology in cardiovascular and immunological research, see related discussions at internal article.